login
Password reminder
Cardiovascular News
Contact the editor Visit Cardiovascular News Twitter feed Visit Cardiovascular News Facebook page
 

Symplicity Renal Denervation System receives Health Canada licence


Wednesday, 18 Apr 2012 15:07
Renal denervation
Renal denervation

Medtronic  has announced that it has received a Health Canada licence for its Symplicity Renal Denervation System to reduce treatment-resistant high blood pressure in patients unresponsive to three or more anti-hypertensive medications. 


“Decreasing a patient’s systolic blood pressure from 160 to 130 mm Hg over a period of six months, which renal denervation has been shown to do, could prevent many heart attacks and strokes from ever happening,” said Barry Rubin, medical director, Peter Munk Cardiac Centre, Toronto, Ontario. “Our multidisciplinary renal denervation programme, which includes interventional radiologists, vascular surgeons, cardiologists, hypertension and kidney specialists will treat many eligible patients in the months ahead.”

Results from the SYMPLICITY HTN-1 trial have shown sustained safety and effectiveness of renal denervation with the system out to three years, and results from the SYMPLICITY HTN-2 trial showed safe, and statistically significant reduction of blood pressure (-33 mg Hg systolic blood pressure) at six months following the procedure and sustained to 12 months. These data were recently presented at the annual American College of Cardiology during an oral session, which was dedicated to renal denervation.


In addition to the licence from Health Canada, the Symplicity Renal Denervation System has received CE mark and a listing with Australia’s Therapeutic Goods Administration (TGA). The Symplicity Renal Denervation System is under investigational use in the United States.


About the Symplicity Renal Denervation System


The Symplicity Renal Denervation System accomplishes renal denervation via a minimally invasive procedure that disables sympathetic nerves located in the renal artery walls, which has been shown to reduce high blood pressure. The system consists of a generator and a flexible catheter. The catheter is introduced through the femoral artery in the upper thigh and is threaded up into the renal artery near each kidney. Once in place, the tip of the catheter delivers low-power radiofrequency energy according to a proprietary algorithm, or pattern, to ablate the surrounding sympathetic nerves. The procedure does not involve a permanent implant.




Add New Comment

Related Items


Most popular


Men believe “long working hours” stop women from being interventional cardiologists
Wednesday, 15 Jul 2015
According to a new survey published in EuroIntervention, men state that the long working hours and the need to be on call that is associated with being an interventional cardiologist are the key ... Men believe “long working hours” stop women from being interventional cardiologists

Boston Scientific launches bioresorbable scaffold trial
Monday, 20 Jul 2015
Boston Scientific has initiated a study to evaluate its fully resorbable scaffold technology. FAST (Fully absorbable scaffold feasibility study) is a prospective, single-arm study designed to assess ... Boston Scientific launches bioresorbable scaffold trial

Vascular Solutions introduces two new versions of Turnpike catheters
Thursday, 18 Jun 2015
All three versions of the Turnpike are over-the-wire catheters with an advanced shaft design that provides superior tracking and advancement over a 0.014” guidewire for use in complex coronary and ... Vascular Solutions introduces two new versions of Turnpike catheters

Features


Strut coverage: Optical coherence tomography and new stent technologies
Monday, 20 Jul 2015
Tim Kinnaird explores the risk of stent thrombosis with current technologies, how new technologies may be able to reduce this risk, and how OCT can help to assess this risk. Strut coverage: Optical coherence tomography and new stent technologies

The second generation of drug-eluting stents with biodegradable polymers may have potential advantages
Monday, 06 Jul 2015
Drug-eluting stents with biodegradable polymers have theoretical advantages over drug-eluting stents with permanent polymers—even second-generation drug-eluting stents. The second generation of drug-eluting stents with biodegradable polymers may have potential advantages

Profiles


Deepak L Bhatt
Tuesday, 09 Jun 2015
Deepak L Bhatt (Executive director of Interventional Cardiovascular Programs, Brigham and Women’s H... Deepak L Bhatt

Flavio Ribichini
Thursday, 05 Mar 2015
Flavio Ribichini speaks to Cardiovascular News about being involved in the first use of primary ... Flavio Ribichini

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions